EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC

Trial Details

NCT ID

NCT07637448

Phase

PHASE2

Sponsor

Nanfang Hospital, Southern Medical University

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• EGFR-TKIs Combined with PD-1 Monoclonal Antibody

Locations (sample)

• Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

• Patients with histologically or cytologically confirmed, previously untreated EGFR-mutant (19del/L858R) locally advanced or metastatic (stage IIIB/…
• Male or female patients aged ≥ 18 years;
• Patients who are willing to receive third-generation EGFR-TKI targeted therapy, followed by maintenance therapy with a PD-1 antibody during the sta…
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.